Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of alzheimer's disease

Clinical Pharmacokinetics

Volumn 52, Issue 4, 2013, Pages 225-241

  Noetzli, Muriel ^a   Eap, Chin B ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE; CHOLINE ACETYLTRANSFERASE; CITICOLINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; NICERGOLINE; NICOTINIC RECEPTOR; PARACETAMOL; PLACEBO; QUINIDINE; RIVASTIGMINE;

ALZHEIMER DISEASE; BINDING AFFINITY; CONSTIPATION; DEMENTIA; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PREVALENCE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT RESPONSE; VOMITING;

AGING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; HUMANS; INDANS; MEMANTINE; PHARMACOGENETICS; PHENYLCARBAMATES; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84877058712     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0038-9     Document Type: Review

References (140)

1. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-8.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-7.
3. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry. 2007;20(4):380-5.
4. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-52.
5. Blennow K, De Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387-403.
6. Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology. 2010;59(4-5):221-9.
7. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306(3):821-7.
8. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm. 2006;113(11):1625-44.
9. Riederer P, Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm. 2006;113(11):1671-7.
10. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol. 2003;2(8):503-5.
11. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-41.
12. Obulesu M, Somashekhar R, Venu R. Genetics of Alzheimer's disease: an insight into presenilins and apolipoprotein e instigated neurodegeneration. Int J Neurosci. 2011;121(5):229-36.
13. Crentsil V. The pharmacogenomics of Alzheimer's disease. Ageing Res Rev. 2004;3(2):153-69.
14. Sleegers K, Lambert JC, Bertram L, et al. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010;26(2):84-93.
15. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010;19(R1):R4-11.
16. FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm. Accessed 19 Mar 2012.
17. European Medicine Agency. Search for medicines. http://www.ema.europa.eu/ ema/index.jsp?curl=/pages/home/Home-Page.jsp. Accessed 19 Mar 2012.
18. Compendium Suisse des Medicaments. Basel, Switzerland: Documed SA. http://www.compendium.ch/. Accessed 19 Mar 2012.
19. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719-39.
20. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006; (2):CD003154.
21. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-97.
22. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1):CD005593.
23. Raschetti R, Maggini M, Sorrentino GC, et al. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol. 2005;61(5-6):361-8.
24. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56(11):1388-93.
25. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003;169(6):557-64.
26. Clerici F, Vanacore N, Elia A, et al. Memantine in moderately-severe-to- severe Alzheimer's disease: a postmarketing surveillance study. Drugs Aging. 2009;26(4):321-32.
27. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
28. Van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat. 2009;5:237-47.
29. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667-71.
30. Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res. 2007;4(4):479-500.
31. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8.
32. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453-78.
33. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 1999;12(4):307-23.
34. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol. 2006;9(1):101-24.
35. Fang L, Pan Y, Muzyka JL, et al. Active site gating and substrate specificity of butyrylcholinesterase and acetylcholinesterase: insights from molecular dynamics simulations. J Phys Chem B. 2011;115(27):8797-805.
36. Kosasa T, Kuriya Y, Matsui K, et al. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur J Pharmacol. 1999;386(1):7-13.
37. Villalobos A, Blake JF, Biggers CK, et al. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. J Med Chem. 1994;37(17):2721-34.
38. Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
39. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990;46(21):1553-8.
40. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000;60(5):1095-122.
41. Maelicke A, Schrattenholz A, Samochocki M, et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res. 2000;113(1-2):199-206.
42. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998;20(4):634-47.
43. Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999;19(6):513-21.
44. Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet. 2002;41(3):225-34.
45. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 2000;20(1):1-12.
46. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res. 1993;98:431-8.
47. Enz A, Boddeke H, Gray J, et al. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci. 1991;640:272-5.
48. Thomson Reuters. Micromedex® Healthcare Series 2.0, Drug® evaluations rivastigmine. http://www.thomsonhc.com/micromedex2/librarian. Accessed 26 Sep 2012.
49. Bryson HM, Benfield P. Donepezil. Drugs Aging. 1997;10:234-9.
50. Lenzken SC, Lanni C, Govoni S, et al. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact. 2007;165(2):138-45.
51. Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int. 2008;53(5):103-11.
52. Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem. 2004;90(6):1489-99.
53. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003;28(3-4):515-22.
54. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699-723.
55. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders: memantine, a new hope. Pharmacol Res. 2005;51(1):1-17.
56. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(Suppl 1):S23-32.
57. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci. 2007;8(10):803-8.
58. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-24.
59. Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract. 2006;60(1):110-8.
60. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.
61. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-7.
62. Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin. 2010;26(2):263-9.
63. Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med. 2012;366(10):957-9.
64. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm. 1997;54(24):2805-10.
65. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):223-9.
66. FDA. Center for Drug Evaluation and Research. Application number: 022568. Clinical pharmacology and biopharmaceutics review(s). http://www.accessdata. fda.gov/drugsatfda-docs/nda/2010/022568Orig1s000ClinPharmR.pdf. Accessed 26 Sep 2012.
67. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol. 1998;46(Suppl. 1):7-12.
68. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol. 1998;46(Suppl 1):13-8.
69. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol. 1993;33(11):1086-91.
70. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol. 1998;46(Suppl 1):19-24.
71. Matsui K, Taniguchi S, Yoshimura T. Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. Xenobiotica. 1999;29(11):1059-72.
72. Matsui K, Mishima M, Nagai Y, et al. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos. 1999;27(12):1406-14.
73. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol. 1998;46(Suppl 1):30-4.
74. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol. 1998;46(Suppl 1):25-9.
75. Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol. 2004;58(Suppl 1):18-24.
76. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol. 1998;46(Suppl 1):56-60.
77. Reyes JF, Vargas R, Kumar D, et al. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol. 2004;58(Suppl 1):9-17.
78. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991;50(4):420-8.
79. Jones RW, Cooper DM, Haworth J, et al. The effect of food on the absorption of galanthamine in healthy elderly volunteers. Br J Clin Pharmacol. 1996;42:671P-2P.
80. Zhao Q, Janssens L, Verhaeghe T, et al. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin. 2005;21(10):1547-54.
81. Zhao Q, Brett M, Van ON, et al. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2002;42(9):1002-10.
82. Zhao Q, Iyer GR, Verhaeghe T, et al. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol. 2002;42:428-36.
83. Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos. 2002;30(5):553-63.
84. Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics. 1999;9:661-8.
85. Trademark (galantamine HBR) extended-release capsules. http://www.accessdata.fda.gov/drugsatfda-docs/label/2004/021615lbl.pdf. Accessed 26 Apr 2012.
86. Piotrovsky V, Van Peer A, Van Osselaer N, et al. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol. 2003;43(5):514-23.
87. Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. 2008;83(1):106-14.
88. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand. 1998;97(4):244-50.
89. Gobburu JV, Tammara V, Lesko L, et al. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. J Clin Pharmacol. 2001;41(10):1082-90.
90. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging. 1998;13(5):391-411.
91. Mercier F, Lefevre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23(12):3199-204.
92. Cummings J, Lefevre G, Small G, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology. 2007;69(4 Suppl 1):S10-3.
93. Lefevre G, Buche M, Sedek G, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol. 2009;49(4):430-43.
94. Schran HF. The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase inhibitor SDZ ENA 713. Pharm Res. 1996; 13(PPDM 8143):S428.
95. EMEA. Memantine scientific discussion. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Scientific-Discussion/human/000378/WC500029674.pdf. Accessed 26 Apr 2012.
96. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134-43.
97. Liu MY, Meng SN, Wu HZ, et al. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther. 2008;30(4):641-53.
98. Mobius HJ, Stoffler A, Graham SM. Memantine hydrochloride: pharmacological and clinical profile. Drugs Today (Barc). 2004;40(8):685-95.
99. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599-612.
100. EMEA. EPAR (european public assessment report): Axura. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000378/WC500029678.pdf. Accessed 26 Apr 2012.
101. Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004;60(8):583-9.
102. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998;54(2):342-52.
103. Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol. 2011;7(2):159-74.
104. Freudenthaler S, Meineke I, Schreeb KH, et al. Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol. 1998;46(6):541-6.
105. Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther. 2005;27(10):1596-606.
106. The human cytochrome P450 (CYP) allele nomenclature database. http://www.cypalleles.ki.se. Accessed 26 Apr 2012.
107. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23-37.
108. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689-723.
109. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006;62(9):721-6.
110. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761-7.
111. Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics. 2011;21(4):225-30.
112. Chianella C, Gragnaniello D, Maisano Delser P. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol. 2011;67(11):1147-57.
113. Noetzli M, Guidi M, Ebbing K, et al. Relationship of CYP2D6, CYP3A, POR and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit (in press).
114. Dobrinas M, Eap CB. Cytochrome P4503A pharmacogenetics. HIV PGX. 2007;2(2):1-5.
115. Siccardi M, D'Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;47:1222-5.
116. Oneda B, Crettol S, Jaquenoud Sirot E. The P450 oxidoreductase is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogen Genomics. 2009;19(11):877-83.
117. Oleson L, von Moltke LL, Greenblatt DJ, et al. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica. 2010;40(2):146-62.
118. Magliulo L, Dahl ML, Lombardi G, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47-54.
119. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61.
120. Scacchi R, Gambina G, Moretto G, et al. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(4):502-7.
121. Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006;16(11):771-4.
122. Harold D, Macgregor S, Patterson CE, et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease. Pharmacogenet Genomics. 2006;16(2):75-7.
123. Pola R, Flex A, Ciaburri M, et al. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett. 2005;382(3):338-41.
124. Klimkowicz-Mrowiec A, Marona M, Spisak K, et al. Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;32(1):26-31.
125. Weiner DM, Goodman MW, Colpitts TM, et al. Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias. Am J Pharmacogenomics. 2004;4(2):119-28.
126. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011;10(3):241-52.
127. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 1995;92(26):12260-4.
128. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-95.
129. Rigaud AS, Traykov L, Latour F, et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics. 2002;12(5):415-20.
130. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000;57(1):94-9.
131. Kanaya K, Abe S, Sakai M, et al. Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype. Geriatr Gerontol Int. 2010;10(1):25-31.
132. Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20(4):254-61.
133. Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12(2):69-77.
134. Suh GH, Jung HY, Lee CU, et al. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;21(1):33-9.
135. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54(12):2261-8.
136. Blesa R, Aguilar M, Casanova JP, et al. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(4):248-54.
137. Farlow M, Lane R, Kudaravalli S, et al. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. Pharmacogenomics J. 2004;4(5):332-5.
138. Noetzli M, Guidi M, Ebbing K, et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet (in press). doi: 10.1007/s40262-013-0032-2.
139. Zhao Q, Tang XC. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol. 2002;455(2-3):101-7.
140. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol. 2005;45(5):519-28.